➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Harvard Business School
Merck
Baxter
Mallinckrodt

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Sacubitril

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Sacubitril?

Sacubitril is an investigational drug.

There have been 59 clinical trials for Sacubitril. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are Heart Failure, Myocardial Infarction, and Infarction. The leading clinical trial sponsors are Novartis Pharmaceuticals, Brigham and Women's Hospital, and Vanderbilt University Medical Center.

There are forty-four US patents protecting this investigational drug and five hundred and eleven international patents.

Recent Clinical Trials for Sacubitril
TitleSponsorPhase
Early Treatment of ARNI on Myocardial Remodeling and ProgressRenJi HospitalPhase 4
NATriuretic Response to Expansion and dIUretics in huMans With Heart FailureAbbottN/A
NATriuretic Response to Expansion and dIUretics in huMans With Heart FailureSaint-Louis-Lariboisière University HospitalsN/A

See all Sacubitril clinical trials

Clinical Trial Summary for Sacubitril

Top disease conditions for Sacubitril
Top clinical trial sponsors for Sacubitril

See all Sacubitril clinical trials

US Patents for Sacubitril

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sacubitril   Start Trial Organic compounds INTRA-CELLULAR THERAPIES, INC. (New York, NY)   Start Trial
Sacubitril   Start Trial Synthetic linear apelin mimetics for the treatment of heart failure NOVARTIS AG (Basel, CH)   Start Trial
Sacubitril   Start Trial Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Harvard Business School
Merck
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.